English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 913775      Online Users : 1205
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version

    Category

    Loading community tree, please wait....

    Year

    Loading year class tree, please wait....

    Items for Author "Furuse, J" 

    Return to Browse by Author

    Showing 10 items.

    Collection Date Title Relation Bitstream
    [陳立宗] 會議論文/會議摘要 2014-01 EVOLVE-1: Phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib -
    [陳立宗] 期刊論文 2014-07-02 Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib the EVOLVE-1 randomized clinical trial -
    [陳立宗] 期刊論文 2016-08 Integrative biomarker analyses indicate etiological variations in hepatocellular carcinoma -
    [陳立宗] 期刊論文 2017-08 A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo -
    [陳立宗] 會議論文/會議摘要 2019-02 A phase II trial of TAS-120 in patients with intrahepatic cholangiocarcinoma harboring FGFR2 gene rearrangements -
    [陳立宗] 會議論文/會議摘要 2021-07 Primary results of phase 2 FOENIX-CCA2: The irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements -
    [陳立宗] 會議論文/會議摘要 2021-09 Primary results of phase 2 FOENIX-CCA2: the irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma (iCCA) with FGFR2 fusions/rearrangements -
    [陳立宗] 會議論文/會議摘要 2022-06 Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements -
    [陳立宗] 期刊論文 2023-01-19 Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma -
    [陳立宗] 期刊論文 2024-06-17 Plain language summary of the FOENIX-CCA2 study: Futibatinib for people with advanced bile duct cancer -

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback